Janssen Receives EC's Approval for Expanded Use of Erleada (apalutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer
Shots:
- The EC’s approval is based on P-III TITAN study assessing Erleada + ADT vs PBO + ADT in 1052 patients in a ratio (1:1) with mHSPC regardless of the extent of disease or prior docetaxel treatment history across 23 countries
- The P-III TITAN study results: improvement in OS with a 33% reduction in risk of death; 52% reduction in rPFS; OS rates after a median follow up of 22.7mos. (82% vs 74%)
- Erleada is an androgen receptor inhibitor- indicated to treat patients with nmCRPC who are at high risk of developing mHSPC in the EU
Click here to read full press release/ article
Ref: Janssen | Image: Janssen
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com